Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide
Antimicrobial Agents and Chemotherapy, Volume 53, No. 5, Year 2009
Notification
URL copied to clipboard!
Description
In this study, we evaluated baseline susceptibility to bevirimat (BVM), the first in a new class of antiretroviral agents, maturation inhibitors. We evaluated susceptibility to BVM by complete gag genotypic and phenotypic testing of 20 patient-derived human immunodeficiency virus type 1 isolates and 20 site-directed mutants. We found that reduced BVM susceptibility was associated with naturally occurring polymorphisms at positions 6, 7, and 8 in Gag spacer peptide 1. Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Authors & Co-Authors
van Eygen, Veerle
Belgium, Mechelen
Virco Bvba
Verheyen, Ann
Belgium, Mechelen
Virco Bvba
Steegen, Kim
Belgium, Mechelen
Virco Bvba
Verlinden, Yvan
Belgium, Mechelen
Virco Bvba
Stuyver, Lieven J.
Belgium, Mechelen
Virco Bvba
Statistics
Citations: 65
Authors: 5
Affiliations: 1
Identifiers
Doi:
10.1128/AAC.01650-08
ISSN:
10986596
Research Areas
Health System And Policy